Qiagen Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Qiagen yıllık ortalama 20.3% oranında kazançlarını artırırken, Life Sciences sektöründe kazançlar growing at 13.8% annual. Gelirler growing yılda ortalama 5.3% oranında artmaktadır. Qiagen'in özkaynak karlılığı 2.1% ve net marjı 3.7%'dir.

Anahtar bilgiler

20.3%

Kazanç büyüme oranı

20.3%

EPS büyüme oranı

Life Sciences Sektör Büyümesi21.5%
Gelir büyüme oranı5.3%
Özkaynak getirisi2.1%
Net Marj3.7%
Sonraki Kazanç Güncellemesi06 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S

Oct 11
Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

Sep 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

May 21
With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

May 03
Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Mar 20
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Feb 13
Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Jan 23
Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

Dec 08
These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Oct 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

Sep 09

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Sep 04
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jul 17
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen: Major Asset Growth Needed In Post-Covid World

Jun 22

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

May 23
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Apr 18
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Feb 15
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued

Feb 14

Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated

Feb 07

If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Jan 18
If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases

Jan 06

A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jan 04
A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati

Dec 13

Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M

Nov 07

We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Oct 31
We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Qiagen stock down after BHF downgrades rating to Neutral

Oct 10

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Oct 04
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate

Sep 14

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Aug 25
Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Jul 28
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Gelir ve Gider Dağılımı

Qiagen nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NYSE:QGEN Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 241,94073568194
31 Mar 241,939337570195
31 Dec 231,965341579199
30 Sep 231,956485600188
30 Jun 231,978337593198
31 Mar 231,999353599198
31 Dec 222,142423604190
30 Sep 222,226488618178
30 Jun 222,261539616177
31 Mar 222,313563606180
31 Dec 212,252513584190
30 Sep 212,240311604184
30 Jun 212,190480572182
31 Mar 212,065449549162
31 Dec 201,870359525149
30 Sep 201,713191522137
30 Jun 201,61214517142
31 Mar 201,550-31530151
31 Dec 191,526-41530157
30 Sep 191,516-25502164
30 Jun 191,511196492164
31 Mar 191,507188508163
31 Dec 181,502190497162
30 Sep 181,49690476162
30 Jun 181,48278474158
31 Mar 181,45355466157
31 Dec 171,41840478154
30 Sep 171,38789467145
30 Jun 171,36275480143
31 Mar 171,34782480147
31 Dec 161,33880470150
30 Sep 161,320123485157
30 Jun 161,296123471157
31 Mar 161,281126450148
31 Dec 151,281130445147
30 Sep 151,293104475151
30 Jun 151,315105484157
31 Mar 151,326113487162
31 Dec 141,345116490164
30 Sep 141,345151487163
30 Jun 141,331157487156
31 Mar 141,31572487152
31 Dec 131,30269486146

Kaliteli Kazançlar: QGEN büyük bir tek seferlik zarar ile $96.4M, 30th June, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: QGEN 'nin mevcut net kar marjları (3.7%) geçen yılın (17%) değerinden daha düşüktür.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: QGEN şirketinin kazançları son 5 yılda yılda 20.3% oranında önemli ölçüde arttı.

Büyüme Hızlandırma: QGEN 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: QGEN geçtiğimiz yıl negatif kazanç büyümesine ( -78.4% ) sahipti ve bu da onu Life Sciences sektör ortalamasıyla ( -10.8% ) karşılaştırmayı zorlaştırıyordu.


Özkaynak Getirisi

Yüksek ROE: QGEN 'nin Özsermaye Getirisi ( 2.1% ) düşük olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin